← back to search

Josh F. Peterson

Vanderbilt University Medical Center · US
Area of research
Genetics · Pharmacology
Research interest
Research interests include Genomics and Rare Diseases, BRCA gene mutations in cancer, Pharmacogenetics and Drug Metabolism, and Astrophysics and Cosmic Phenomena.
h-index
56
citations
15,132
works
279
NIH funding
primary concept
Medicine
email

Recent publications

Governing real-world health data as a public utility.
2026cited by 0position: contributordoi
Characterizing trends in clinical genetic testing: A single-center analysis of EHR data from 1.8 million patients over two decades.
2025cited by 10position: contributordoi
Covering medical care costs for participants in the eMERGE Network: Challenges for equity and implementation
Genetics in Medicine 2025cited by 3position: middledoi
Covering medical care costs for participants in the eMERGE Network: Challenges for equity and implementation.
2025cited by 3position: contributordoi
Beyond Carrier Status: CFTR Heterozygosity as an Overlooked Clinical Risk Factor for Pancreatitis.
2025cited by 2position: contributordoi
Implementing integrated genomic risk assessments for breast cancer: lessons learned from the Electronic Medical Records and Genomics study.
2025cited by 2position: contributordoi
A standard-based taxonomy of features that affect user response to clinical decision support alerts.
2025cited by 0position: contributordoi
Selection, optimization and validation of ten chronic disease polygenic risk scores for clinical implementation in diverse US populations
Nature Medicine 2024cited by 182position: middledoi
Selection, optimization and validation of ten chronic disease polygenic risk scores for clinical implementation in diverse US populations.
2024cited by 169position: contributordoi
Leveraging generative AI to prioritize drug repurposing candidates for Alzheimer’s disease with real-world clinical validation
npj Digital Medicine 2024cited by 59position: middledoi
Leveraging large language models for generating responses to patient messages-a subjective analysis.
2024cited by 57position: contributordoi
Leveraging generative AI to prioritize drug repurposing candidates for Alzheimer's disease with real-world clinical validation.
2024cited by 35position: contributordoi
Large language models facilitate the generation of electronic health record phenotyping algorithms.
2024cited by 25position: contributordoi
Using large language model to guide patients to create efficient and comprehensive clinical care message.
2024cited by 18position: contributordoi
Diagnostic delay in monogenic disease: A scoping review.
2024cited by 17position: contributordoi
Leveraging explainable artificial intelligence to optimize clinical decision support.
2024cited by 13position: contributordoi
Rationale and design for a pragmatic randomized trial to assess gene-based prescribing for SSRIs in the treatment of depression.
2024cited by 7position: contributordoi
Implementing a pragmatic clinical trial to tailor opioids for chronic pain on behalf of the IGNITE ADOPT PGx investigators.
2024cited by 6position: contributordoi
Pharmacogenomics: Genotype-Driven Medicine.
2024cited by 2position: contributordoi
Returning integrated genomic risk and clinical recommendations: The eMERGE study.
2023cited by 108position: contributordoi
Population Genomic Screening for Three Common Hereditary Conditions : A Cost-Effectiveness Analysis.
2023cited by 53position: contributordoi
Evaluating and mitigating bias in machine learning models for cardiovascular disease prediction.
2023cited by 42position: contributordoi
The phenotype-genotype reference map: Improving biobank data science through replication.
2023cited by 19position: contributordoi
Familial Hypercholesterolemia in the Electronic Medical Records and Genomics Network: Prevalence, Penetrance, Cardiovascular Risk, and Outcomes After Return of Results.
2023cited by 18position: contributordoi
Evaluation of the portability of computable phenotypes with natural language processing in the eMERGE network.
2023cited by 14position: contributordoi
Studying the impact of translational genomic research: Lessons from eMERGE.
2023cited by 12position: contributordoi
Prospective, multi-site study of healthcare utilization after actionable monogenic findings from clinical sequencing.
2023cited by 8position: contributordoi
Phenotypic presentation of Mendelian disease across the diagnostic trajectory in electronic health records.
2023cited by 7position: contributordoi
Scanning the medical phenome to identify new diagnoses after recovery from COVID-19 in a US cohort.
2023cited by 7position: contributordoi
Risk factors affecting polygenic score performance across diverse cohorts
eLife 2023cited by 4position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 11 papers (2020–2024)Richard Sharp · BioElectronics (United States)7 papers (2019–2023)Marc S. Williams · Danville Community College7 papers (2019–2023)Julie A. Johnson · University of North Carolina at Chapel Hill7 papers (2019–2024)Joshua C. Denny · Cambridge School7 papers (2019–2023)Kathryn V Blake · Nemours Children's Health System6 papers (2019–2024)Laura J Rasmussen-Torvik · University of Virginia5 papers (2019–2025)Adam S. Gordon · Lurie Children's Hospital5 papers (2019–2022)Larisa H. Cavallari · University of North Carolina at Chapel Hill5 papers (2019–2024)Jonathan S. Schildcrout · Cancer Research And Biostatistics5 papers (2020–2023)Philip E Empey · University of Pittsburgh4 papers (2019–2021)Almut G. Winterstein · Florida Museum of Natural History4 papers (2020–2024)Sara L. Van Driest · Office of the Director4 papers (2020–2024)Laura B. Ramsey · Kansas City Public Schools3 papers (2019–2021) · 3 papers (2024–2024)Sarah T. Bland · Vanderbilt University Medical Center3 papers (2020–2025) · 3 papers (2022–2023)Maureen E. Smith · National Organization for Rare Disorders3 papers (2020–2021) · 3 papers (2020–2021)Laney K. Jones · Michigan United3 papers (2022–2023)